Wednesday, November 16, 2016

BRIEF-Gilead announces top-line results from two phase 3 studies

* Gilead Sciences Inc - non-inferiority was not achieved for

key secondary endpoint of response rate in total symptom score

(TSS)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)